145 related articles for article (PubMed ID: 8912182)
1. Expression of the RET proto-oncogene in normal human tissues, pheochromocytomas, and other tumors of neural crest origin.
Takaya K; Yoshimasa T; Arai H; Tamura N; Miyamoto Y; Itoh H; Nakao K
J Mol Med (Berl); 1996 Oct; 74(10):617-21. PubMed ID: 8912182
[TBL] [Abstract][Full Text] [Related]
2. The RET proto-oncogene in sporadic pheochromocytomas.
Takaya K; Yoshimasa T; Arai H; Tamura N; Miyamoto Y; Itoh H; Nakao K
Intern Med; 1996 Jun; 35(6):449-52. PubMed ID: 8835594
[TBL] [Abstract][Full Text] [Related]
3. Expression of the ret proto-oncogene in human medullary thyroid carcinomas and pheochromocytomas of MEN 2A.
Miya A; Yamamoto M; Morimoto H; Tanaka N; Shin E; Karakawa K; Toyoshima K; Ishizaka Y; Mori T; Takai S
Henry Ford Hosp Med J; 1992; 40(3-4):215-9. PubMed ID: 1362408
[TBL] [Abstract][Full Text] [Related]
4. Rudolf-Virchow-Preis 1995. The role of RET proto-oncogene mutation analysis in the diagnosis of multiple endocrine neoplasia type 2 (MEN 2) gene carriers and in the discrimination of sporadic and familial medullary thyroid carcinomas and pheochromocytomas.
Komminoth P
Verh Dtsch Ges Pathol; 1995; 79():L-LV. PubMed ID: 8600671
[TBL] [Abstract][Full Text] [Related]
5. The ret proto-oncogene is consistently expressed in human pheochromocytomas and thyroid medullary carcinomas.
Santoro M; Rosati R; Grieco M; Berlingieri MT; D'Amato GL; de Franciscis V; Fusco A
Oncogene; 1990 Oct; 5(10):1595-8. PubMed ID: 1701232
[TBL] [Abstract][Full Text] [Related]
6. Tumor-specific mutations in the tyrosine kinase domain of the RET proto-oncogene in pheochromocytomas of sporadic type.
Yoshimoto K; Tanaka C; Hamaguchi S; Kimura T; Iwahana H; Miyauchi A; Itakura M
Endocr J; 1995 Apr; 42(2):265-70. PubMed ID: 7627271
[TBL] [Abstract][Full Text] [Related]
7. Ret protein expression in adrenal medullary hyperplasia and pheochromocytoma.
Powers JF; Brachold JM; Tischler AS
Endocr Pathol; 2003; 14(4):351-61. PubMed ID: 14739491
[TBL] [Abstract][Full Text] [Related]
8. Expression of RET and its ligand complexes, GDNF/GFRalpha-1 and NTN/GFRalpha-2, in medullary thyroid carcinomas.
Frisk T; Farnebo F; Zedenius J; Grimelius L; Höög A; Wallin G; Larsson C
Eur J Endocrinol; 2000 Jun; 142(6):643-9. PubMed ID: 10822229
[TBL] [Abstract][Full Text] [Related]
9. High levels of tyrosine phosphorylated proto-ret in sporadic phenochromocytomas.
Le Hir H; Colucci-D'Amato LG; Charlet-Berguerand N; Plouin PF; Bertagna X; de Franciscis V; Thermes C
Cancer Res; 2000 Mar; 60(5):1365-70. PubMed ID: 10728700
[TBL] [Abstract][Full Text] [Related]
10. A single missense mutation in codon 918 of the RET proto-oncogene in sporadic medullary thyroid carcinomas.
Maeda S; Namba H; Takamura N; Tanigawa K; Takahashi M; Noguchi S; Nagataki S; Kanematsu T; Yamashita S
Endocr J; 1995 Apr; 42(2):245-50. PubMed ID: 7627269
[TBL] [Abstract][Full Text] [Related]
11. RET proto-oncogene point mutations in sporadic neuroendocrine tumors.
Komminoth P; Roth J; Muletta-Feurer S; Saremaslani P; Seelentag WK; Heitz PU
J Clin Endocrinol Metab; 1996 Jun; 81(6):2041-6. PubMed ID: 8964826
[TBL] [Abstract][Full Text] [Related]
12. Mutation of the RET proto-oncogene is correlated with RET immunostaining in subpopulations of cells in sporadic medullary thyroid carcinoma.
Eng C; Thomas GA; Neuberg DS; Mulligan LM; Healey CS; Houghton C; Frilling A; Raue F; Williams ED; Ponder BA
J Clin Endocrinol Metab; 1998 Dec; 83(12):4310-3. PubMed ID: 9851769
[TBL] [Abstract][Full Text] [Related]
13. Familial medullary thyroid carcinoma: not a distinct entity? Genotype-phenotype correlation in a large family.
Moers AM; Landsvater RM; Schaap C; Jansen-Schillhorn van Veen JM; de Valk IA; Blijham GH; Höppener JW; Vroom TM; van Amstel HK; Lips CJ
Am J Med; 1996 Dec; 101(6):635-41. PubMed ID: 9003111
[TBL] [Abstract][Full Text] [Related]
14. Identification and analysis of the ret proto-oncogene promoter region in neuroblastoma cell lines and medullary thyroid carcinomas from MEN2A patients.
Itoh F; Ishizaka Y; Tahira T; Yamamoto M; Miya A; Imai K; Yachi A; Takai S; Sugimura T; Nagao M
Oncogene; 1992 Jun; 7(6):1201-6. PubMed ID: 1350670
[TBL] [Abstract][Full Text] [Related]
15. Absence of mutations at codon 768 of the RET proto-oncogene in sporadic and hereditary pheochromocytomas.
Yoshimoto K; Kimura T; Tanaka C; Moritani M; Iwahana H; Itakura M
Endocr J; 1996 Feb; 43(1):109-14. PubMed ID: 8732460
[TBL] [Abstract][Full Text] [Related]
16. Expression analysis of RET and the GDNF/GFRalpha-1 and NTN/GFRalpha-2 ligand complexes in pheochromocytomas and paragangliomas.
Edström E; Frisk T; Farnebo F; Höög A; Bäckdahl M; Larsson C
Int J Mol Med; 2000 Oct; 6(4):469-74. PubMed ID: 10998441
[TBL] [Abstract][Full Text] [Related]
17. Sporadic and familial pheochromocytomas are associated with loss of at least two discrete intervals on chromosome 1p.
Benn DE; Dwight T; Richardson AL; Delbridge L; Bambach CP; Stowasser M; Gordon RD; Marsh DJ; Robinson BG
Cancer Res; 2000 Dec; 60(24):7048-51. PubMed ID: 11156410
[TBL] [Abstract][Full Text] [Related]
18. Adrenal ganglioneuromas in children with multiple endocrine neoplasia type 2: a report of two cases.
Lora MS; Waguespack SG; Moley JF; Walvoord EC
J Clin Endocrinol Metab; 2005 Jul; 90(7):4383-7. PubMed ID: 15827098
[TBL] [Abstract][Full Text] [Related]
19. Genetic aberrance of sporadic MEN 2A component tumours: analysis of RET.
Cho NH; Lee HW; Lim SY; Kang S; Jung WY; Park CS
Pathology; 2005 Feb; 37(1):10-3. PubMed ID: 15875728
[TBL] [Abstract][Full Text] [Related]
20. Adrenal and extra-adrenal pheochromocytomas in a family with germline RET V804L mutation.
Nilsson O; Tisell LE; Jansson S; Ahlman H; Gimm O; Eng C
JAMA; 1999 May; 281(17):1587-8. PubMed ID: 10235148
[No Abstract] [Full Text] [Related]
[Next] [New Search]
